Omeros ROE 2010-2025 | OMER
Current and historical return on equity (ROE) values for Omeros (OMER) over the last 10 years. Return on equity can be defined as the amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested.
| Omeros ROE - Return on Equity Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Shareholder's Equity | Return on Equity |
| 2025-03-31 | $-0.15B | $-0.21B | 89.94% |
| 2024-12-31 | $-0.16B | $-0.18B | 117.07% |
| 2024-09-30 | $-0.13B | $-0.15B | 142.93% |
| 2024-06-30 | $-0.14B | $-0.13B | 238.30% |
| 2024-03-31 | $-0.12B | $-0.07B | 543.82% |
| 2023-12-31 | $-0.12B | $-0.03B | -1275.68% |
| 2023-09-30 | $0.02B | $-0.01B | 54.05% |
| 2023-06-30 | $0.04B | $0.02B | 141.38% |
| 2023-03-31 | $0.05B | $0.06B | 303.23% |
| 2022-12-31 | $0.05B | $0.09B | 9600.00% |
| 2022-09-30 | $0.20B | $-0.05B | -1333.33% |
| 2022-06-30 | $0.19B | $-0.03B | -280.14% |
| 2022-03-31 | $0.20B | $-0.01B | -160.00% |
| 2021-12-31 | $0.19B | $0.02B | -109.76% |
| 2021-09-30 | $-0.12B | $-0.26B | 58.22% |
| 2021-06-30 | $-0.14B | $-0.25B | 82.25% |
| 2021-03-31 | $-0.14B | $-0.22B | 96.79% |
| 2020-12-31 | $-0.14B | $-0.12B | 109.38% |
| 2020-09-30 | $-0.13B | $-0.09B | 105.52% |
| 2020-06-30 | $-0.11B | $-0.16B | 78.97% |
| 2020-03-31 | $-0.09B | $-0.13B | 68.88% |
| 2019-12-31 | $-0.08B | $-0.11B | 66.40% |
| 2019-09-30 | $-0.08B | $-0.14B | 63.54% |
| 2019-06-30 | $-0.10B | $-0.13B | 91.82% |
| 2019-03-31 | $-0.12B | $-0.12B | 132.24% |
| 2018-12-31 | $-0.13B | $-0.10B | 185.40% |
| 2018-09-30 | $-0.12B | $-0.09B | 271.19% |
| 2018-06-30 | $-0.09B | $-0.06B | 445.57% |
| 2018-03-31 | $-0.07B | $-0.03B | 348.72% |
| 2017-12-31 | $-0.05B | $0.00B | 218.56% |
| 2017-09-30 | $-0.06B | $0.01B | 170.99% |
| 2017-06-30 | $-0.06B | $-0.06B | 154.60% |
| 2017-03-31 | $-0.06B | $-0.05B | 157.96% |
| 2016-12-31 | $-0.07B | $-0.04B | 181.33% |
| 2016-09-30 | $-0.07B | $-0.02B | 195.68% |
| 2016-06-30 | $-0.07B | $-0.05B | 236.80% |
| 2016-03-31 | $-0.08B | $-0.04B | 458.82% |
| 2015-12-31 | $-0.08B | $-0.03B | 6080.00% |
| 2015-09-30 | $-0.08B | $-0.01B | 1400.00% |
| 2015-06-30 | $-0.08B | $0.01B | 750.00% |
| 2015-03-31 | $-0.08B | $0.02B | 515.25% |
| 2014-12-31 | $-0.07B | $-0.04B | 389.47% |
| 2014-09-30 | $-0.06B | $-0.03B | 431.37% |
| 2014-06-30 | $-0.05B | $-0.01B | 425.00% |
| 2014-03-31 | $-0.05B | $0.01B | 383.67% |
| 2013-12-31 | $-0.04B | $-0.02B | 228.57% |
| 2013-09-30 | $-0.05B | $-0.02B | 311.86% |
| 2013-06-30 | $-0.05B | $-0.01B | 500.00% |
| 2013-03-31 | $-0.04B | $-0.02B | 355.56% |
| 2012-12-31 | $-0.04B | $-0.01B | 371.43% |
| 2012-09-30 | $-0.04B | $0.00B | 400.00% |
| 2012-06-30 | $-0.04B | $-0.02B | 388.89% |
| 2012-03-31 | $-0.03B | $-0.01B | 2480.00% |
| 2011-12-31 | $-0.03B | $-0.01B | -504.35% |
| 2011-09-30 | $-0.03B | $0.00B | -212.24% |
| 2011-06-30 | $-0.03B | $0.01B | -158.82% |
| 2011-03-31 | $-0.03B | $0.02B | -136.36% |
| 2010-12-31 | $-0.03B | $0.02B | -109.09% |
| 2010-09-30 | $-0.03B | $0.02B | -87.22% |
| 2010-06-30 | $-0.03B | $0.03B | -104.17% |
| 2010-03-31 | $-0.02B | $0.04B | -139.39% |
| 2009-12-31 | $-0.02B | $0.04B | -289.66% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $0.199B | $0.000B |
| Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urological and other surgical and medical procedures. Omeros has four ongoing PharmacoSurgery(TM) clinical development programs, and its lead product candidate, OMS103HP, is being evaluated in Phase 3 clinical trials for use during arthroscopic surgery to improve postoperative joint function and reduce postoperative pain. Omeros is also building a diverse pipeline of preclinical programs targeting inflammation and central nervous system disorders. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $235.957B | 28.04 |
| Boston Scientific (BSX) | United States | $147.560B | 37.59 |
| Stryker (SYK) | United States | $144.011B | 30.10 |
| EssilorLuxottica (ESLOY) | France | $128.708B | 0.00 |
| Medtronic (MDT) | Ireland | $111.928B | 15.99 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.371B | 0.00 |
| Haleon (HLN) | United Kingdom | $48.904B | 27.49 |
| ResMed (RMD) | United States | $36.560B | 27.72 |
| Agilent Technologies (A) | United States | $33.258B | 22.04 |
| GE HealthCare Technologies (GEHC) | United States | $33.082B | 15.84 |
| Terumo (TRUMY) | Japan | $26.680B | 34.37 |
| Insulet (PODD) | United States | $21.438B | 84.69 |
| Koninklijke Philips (PHG) | Netherlands | $21.384B | 15.43 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.060B | 11.71 |
| Baxter (BAX) | United States | $15.713B | 11.81 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $12.872B | 0.00 |
| Demant (WILYY) | Denmark | $9.377B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $9.076B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $6.175B | 21.94 |
| Lantheus Holdings (LNTH) | United States | $5.385B | 13.58 |
| Prestige Consumer Healthcare (PBH) | United States | $4.149B | 18.47 |
| Perrigo (PRGO) | Ireland | $3.664B | 9.30 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.367B | 15.31 |
| ICU Medical (ICUI) | United States | $3.250B | 24.18 |
| Envista Holdings (NVST) | United States | $3.127B | 26.73 |
| GN Store Nord (GNNDY) | Denmark | $2.263B | 19.32 |
| QuidelOrtho (QDEL) | United States | $1.954B | 13.59 |
| LeMaitre Vascular (LMAT) | United States | $1.833B | 41.46 |
| AtriCure (ATRC) | United States | $1.565B | 0.00 |
| Acuren (TIC) | United States | $1.357B | 0.00 |
| Neogen (NEOG) | United States | $1.200B | 15.67 |
| AdaptHealth (AHCO) | United States | $1.161B | 11.81 |
| Green Thumb Industries (GTBIF) | United States | $1.048B | 23.71 |
| BioLife Solutions (BLFS) | United States | $1.046B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.970B | 12.80 |
| Kestra Medical Technologies (KMTS) | United States | $0.904B | 0.00 |
| InMode (INMD) | Israel | $0.844B | 8.55 |
| Evolus (EOLS) | United States | $0.640B | 0.00 |
| CeriBell (CBLL) | United States | $0.624B | 0.00 |
| Owens & Minor (OMI) | United States | $0.602B | 5.08 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.542B | 0.00 |
| Capricor Therapeutics (CAPR) | United States | $0.538B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.524B | 0.00 |
| Valneva SE (VALN) | France | $0.510B | 0.00 |
| Surmodics (SRDX) | United States | $0.417B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.407B | 0.00 |
| SNDL (SNDL) | Canada | $0.339B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.337B | 12.53 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.329B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.329B | 61.50 |
| Canopy Growth (CGC) | Canada | $0.272B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.263B | 22.50 |
| Sanara MedTech (SMTI) | United States | $0.256B | 0.00 |
| Sanuwave Health (SNWV) | United States | $0.254B | 0.00 |
| ZimVie (ZIMV) | United States | $0.253B | 11.63 |
| Cerus (CERS) | United States | $0.252B | 0.00 |
| Cresco Labs (CRLBF) | United States | $0.245B | 0.00 |
| Quanterix (QTRX) | United States | $0.235B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.221B | 0.00 |
| Biote (BTMD) | United States | $0.207B | 6.12 |
| Brainsway (BWAY) | Israel | $0.206B | 55.30 |
| TriSalus Life Sciences (TLSI) | United States | $0.196B | 0.00 |
| Organigram Global (OGI) | Canada | $0.187B | 0.00 |
| High Tide (HITI) | Canada | $0.185B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.179B | 14.57 |
| Verano Holdings (VRNOF) | United States | $0.174B | 0.00 |
| Exagen (XGN) | United States | $0.152B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.140B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.131B | 15.33 |
| Jin Medical (ZJYL) | China | $0.107B | 0.00 |
| MacroGenics (MGNX) | United States | $0.096B | 0.00 |
| Fonar (FONR) | United States | $0.090B | 11.37 |
| Veru (VERU) | United States | $0.090B | 0.00 |
| Quipt Home Medical (QIPT) | United States | $0.087B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.087B | 0.00 |
| Agape ATP (ATPC) | $0.084B | 0.00 | |
| TerrAscend (TSNDF) | Canada | $0.075B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.068B | 0.00 |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Apyx Medical (APYX) | United States | $0.066B | 0.00 |
| Zynex (ZYXI) | United States | $0.064B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.054B | 0.00 |
| Modular Medical (MODD) | United States | $0.042B | 0.00 |
| Nephros (NEPH) | United States | $0.041B | 48.64 |
| United-Guardian (UG) | United States | $0.037B | 13.19 |
| Rockwell Medical (RMTI) | United States | $0.032B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.019B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.019B | 0.00 |
| Safety Shot (SHOT) | United States | $0.018B | 0.00 |
| Flora Growth (FLGC) | United States | $0.017B | 0.00 |
| INLIF (INLF) | $0.012B | 0.00 | |
| Trinity Biotech (TRIB) | Ireland | $0.011B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.011B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.008B | 0.00 |
| Senestech (SNES) | United States | $0.006B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.003B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |